Access the full text.
Sign up today, get DeepDyve free for 14 days.
W. Scheithauer, G. Kornek, M. Raderer, B. Schüll, K. Schmid, E. Kovats, B. Schneeweiss, F. Lang, A. Lenauer, D. Depisch (2003)
Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 7
R. Siegel, K. Miller, A. Jemal (2018)
Cancer statistics, 2018CA: A Cancer Journal for Clinicians, 68
(2019)
Randomizedmulticenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer
M. Tempero, W. Plunkett, V. Haperen, J. Hainsworth, H. Hochster, R. Lenzi, J. Abbruzzese (2003)
Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 18
T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud, Y. Bécouarn, A. Adenis, J. Raoul, S. Gourgou-Bourgade, C. Fouchardière, J. Bennouna, J. Bachet, F. Khemissa-Akouz, D. Péré-Vergé, C. Delbaldo, E. Assenat, B. Chauffert, P. Michel, C. Montoto-Grillot, M. Ducreux (2011)
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.The New England journal of medicine, 364 19
E. Poplin, Yang Feng, J. Berlin, M. Rothenberg, H. Hochster, E. Mitchell, S. Alberts, P. O'dwyer, D. Haller, P. Catalano, D. Cella, A. Benson (2009)
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 23
A. Ko, A. Espinoza, K. Jones, A. Venook, E. Bergsland, R. Kelley, E. Dito, A. Ong, Cherry Hanover, F. Coakley, M. Tempero (2012)
Optimizing the Administration of Fixed-Dose Rate Gemcitabine Plus Capecitabine Using an Alternating-week Schedule: A Dose Finding and Early Efficacy Study in Advanced Pancreatic and Biliary CarcinomasAmerican Journal of Clinical Oncology, 35
Cancer Stat Facts: Pancreatic Cancer
M. Tempero, M. Malafa, M. Al-Hawary, H. Asbun, Andrew Bain, S. Behrman, A. Benson, E. Binder, D. Cardin, Charles Cha, E. Chiorean, V. Chung, B. Czito, Mary Dillhoff, E. Dotan, C. Ferrone, J. Hardacre, W. Hawkins, J. Herman, A. Ko, S. Komanduri, A. Koong, N. Loconte, A. Lowy, C. Moravek, E. Nakakura, E. O’Reilly, Jorge Obando, S. Reddy, C. Scaife, S. Thayer, C. Weekes, R. Wolff, B. Wolpin, J. Burns, S. Darlow (2017)
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN, 15 8
D. Hoff, T. Ervin, F. Arena, E. Chiorean, J. Infante, M. Moore, T. Seay, S. Tjulandin, W. Ma, M. Saleh, M. Harris, M. Reni, S. Dowden, D. Laheru, N. Bahary, R. Ramanathan, J. Tabernero, M. Hidalgo, D. Goldstein, E. Cutsem, Xinyu Wei, J. Iglesias, M. Renschler (2013)
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.The New England journal of medicine, 369 18
Objective Determine whether a regimen of fixed dose rate gemcitabine plus capecitabine is effective and tolerable for advanced pancreatic adenocarcinoma. Methods We performed a retrospective analysis of 62 patients with locally advanced or metastatic pancreatic adenocarcinoma treated at the University of California San Francisco between 2008 and 2016. Treatment was an alternate week schedule of fixed dose rate 1000 mg/m2 gemcitabine and capecitabine 1000 mg/m3 (58 patients), 1200 mg/m3 (12 patients), or 650 mg/m3 (1 patient) for intended 12 cycles. We evaluated overall survival (OS), progression-free survival (PFS), radiologic response, and adverse events necessitating treatment modification. Results For metastatic patients, median OS was 10.3 months (95% confidence interval [CI], 6.7–12.1 months), and PFS was 5.6 months (95% CI, 2.6–7.7 months). In locally advanced patients, OS was 12.0 months (95% CI, 4.9–17.1 months), and PFS was 5.4 months (95% CI, 2.5–9.4 months). Radiologic response for metastatic disease (42 patients) was 19% objective response, 45% stable disease, and 36% progressive disease. Treatment required modification for 22 patients due to adverse events, most frequently hand-foot syndrome (18 patients). Conclusions Alternate week schedule of fixed dose rate gemcitabine and capecitabine was active and tolerable for advanced pancreatic adenocarcinoma. Overall survival and PFS were comparable to first-line treatments. Importantly, adverse effects appear less severe than first-line treatments.
Pancreas – Wolters Kluwer Health
Published: Jan 1, 2019
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.